Sensimed CEO Discloses Financing, Next Steps
Sensimed CEO David Bailey recounts his maiden presentation to OIS and shares information on the company’s recent financing, including a commitment from a new strategic investor. He also explains why ocular volume change could be a clinically relevant measurement for glaucoma.
Participant:
Barry Cheskin
David Bailey has over 30 years of executive experience across major corporations and geographies in the Medical Device and Pharmaceutical industry including seven years as CEO of a USA public company.